Herz

, Volume 37, Issue 6, pp 644–656 | Cite as

Current treatment options in (peri)myocarditis and inflammatory cardiomyopathy

Main topic

Abstract

In inflammatory dilated cardiomyopathy and myocarditis there is—apart from heart failure and antiarrhythmic therapies—no alternative to an aetiologically driven specific treatment. Prerequisite are noninvasive and invasive biomarkers including endomyocardial biopsy and PCR on cardiotropic agents. This review deals with the different etiologies of myocarditis and inflammatory cardiomyopathy including the genetic background, the predisposition for heart failure and inflammation. It analyses the epidemiologic shift in pathogenetic agents in the last 20 years, the role of innate and aquired immunity including the T- and B-cell driven immune responses. The phases and clinical faces of myocarditis are summarized. Up-to-date information on current treatment options starting with heart failure and antiarrhythmic therapy are provided. Although inflammation can resolve spontaneously, specific treatment directed to the causative aetiology is often required. For fulminant, acute and chronic autoreactive myocarditis immunosuppressive treatment is beneficial, while for viral cardiomyopathy and myocarditis ivIg can resolve inflammation and is as successful as interferon therapy in enteroviral and adenoviral myocarditis. For Parvo B19 and HHV6 myocarditis eradication of the virus is still a problem by any of these treatment options. Finally, the potential of stem cell therapy has to be tested in future trials. In virus-negative, autoreactive perimyocardial disease a locoregional approach with intrapericardial instillation of high local doses of triamcinolone acetate has been shown to be highly efficient and with few systemic side-effects.

Keywords

Viral and autoimmune myocarditis Polymerase chain reaction Heart failure therapy Antiviral treatment Intravenous immunoglobulins Immunosuppression 

Aktuelle Behandlungsoptionen bei (Peri-)Myokarditis und inflammatorischer Kardiomyopathie

Zusammenfassung

Bei Myokarditis und inflammatorischer Kardiomyopathie gibt es neben der ohnehin durchzuführenden Herzinsuffizienzbehandlung heute keine echte Alternative zu einer ätiologisch-kausalen Therapie. Diese stützt sich unverändert auf die histologischen, immunhistologischen und molekularbiologischen Befunde aus der Endomyokardbiopsie, wobei nicht-invasive serologische Biomarker (CRP, BNP, Troponin, Gal-3 u. a.) und nicht-invasives Imaging hilfreich bei der Diagnosestellung sind. Die spezifische Therapie orientiert sich bei autoreaktiver virusnegativer Myokarditis an den Ergebnissen der TIMIC- und der ESETCID-Studie, die eine immunsuppressive Behandlung nahelegen, ähnlich wie bei Sarkoidose, Riesenzellmyokarditis und eosinophiler Myokarditis. Bei autoreaktiver, virusnegativer Perimyokarditis vermeidet eine intraperikardiale Triamcinoloninstillation in der Regel die systemischen Nebenwirkungen einer peroralen Kortikoidtherapie. Bei viraler inflammatorischer Kardiomyopathie können i.v.-Immunglobuline stets die Entzündung, die virale Ursache jedoch nicht so regelmäßig eliminieren.

Schlüsselwörter

Virale und autoimmune Myokarditis Polymerasekettenreaktion Herzinsuffizienztherapie Antivirale Behandlung i.v.-Immunglobuline Immunsuppression 

Supplementary material

59_2012_3679_MO1_ESM.pdf (558 kb)
Table 2 and 3 of "Current treatment options in (peri)myocarditis and inflammatory cardiomyopathy" (PDF)

References

  1. 1.
    Kerr WW (1904) Myocarditis. Cal State J Med 2:369–371PubMedGoogle Scholar
  2. 2.
    Maisch B, Noutsias M, Ruppert V et al (2012) Cardiomyopathies – classifications, diagnosis, and treatment. Heart Fail Clin 8:53–78PubMedCrossRefGoogle Scholar
  3. 3.
    Hickie JB, Hall GV (1960) The cardiomyopathies: a report of fifty cases. Australas Ann Med 9:258–270PubMedGoogle Scholar
  4. 4.
    Goodwin JF, Gordon H, Hollman A et al (1961) Clinical aspects of cardiomyopathy. Br Med J 1:69–79PubMedCrossRefGoogle Scholar
  5. 5.
    Anonymous (1980) Report of the WHO/ISFC Task Force on the definition and classification of cardiomyopathies. Br Heart J 44:672–674CrossRefGoogle Scholar
  6. 6.
    Richardson P, McKenna W, Bristow M et al (1996) Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation 93:841–842PubMedCrossRefGoogle Scholar
  7. 7.
    Aretz HT, Billingham M, Olsen E et al (1987) Myocarditis: the Dallas criteria. Hum Pathol 18:619–624PubMedCrossRefGoogle Scholar
  8. 8.
    Maisch B, Bültman B, Factor S et al (1999) World Heart Federation consensus conference’s definition of inflammatory cardiomyopathy (myocarditis): report from two expert committees on histology and viral cardiomyopathy. Heartbeat 4:3–4Google Scholar
  9. 9.
    Maisch B, Portig I, Ristic A et al (2000) Definition of inflammatory cardiomyopathy (myocarditis): on the way to consensus. Herz 25:200–209PubMedCrossRefGoogle Scholar
  10. 10.
    Maisch B, Richter A, Sandmöller A et al (2005) Inflammatory dilated cardiomyopathy (DCMI). Herz 30:535–540PubMedCrossRefGoogle Scholar
  11. 11.
    Pankuweit S, Portig I, Eckhardt H et al (2000) Prevalence of viral genome in endomyocardial biopsies from patients with inflammatory heart muscle disease. Herz 25:221–226PubMedCrossRefGoogle Scholar
  12. 12.
    Paulus WJ, Tschöpe C, Sanderson JE et al (2007) How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 28(20):2539–2550PubMedCrossRefGoogle Scholar
  13. 13.
    Arbustini E, Morbini P, Pilotto A et al (2001) Familial dilated cardiomyopathy: from clinical presentation to molecular genetics. Am J Hum Genet 69:249–260CrossRefGoogle Scholar
  14. 14.
    Mason JW (2003) Myocarditis and dilated cardiomyopathy: an inflammatory link. Cardiovasc Res 60:5–10PubMedCrossRefGoogle Scholar
  15. 15.
    Shaw T, Elliot P, McKenna WJ (2002) Dilated cardiomyopathy: a genetically heterogeneous disease. Lancet 360:654–655PubMedCrossRefGoogle Scholar
  16. 16.
    Maron BJ, Towbin JA, Thiene G et al (2006) Contemporary definitions and classification of the cardiomyopathies: an American Heart Association scientific statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 113:1807–1816PubMedCrossRefGoogle Scholar
  17. 17.
    Elliott P, Andersson B, Arbustini E et al (2008) Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 29:270–276PubMedCrossRefGoogle Scholar
  18. 18.
    Pankuweit S, Richter A, Ruppert V et al (2009) Classification of cardiomyopathies and indication for endomyocardial biopsy revisited. Herz 34:55–62PubMedCrossRefGoogle Scholar
  19. 19.
    Mestroni L, Maisch B, McKenna WJ et al (1999) Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy. Eur Heart J 20(2):93–102PubMedCrossRefGoogle Scholar
  20. 20.
    Hershberger RE, Cowan J, Morales A, Siegfried JD (2009) Progress with genetic cardiomyopathies: screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Heart Fail 2(3):253–261PubMedCrossRefGoogle Scholar
  21. 21.
    Kimura A (2008) Molecular aetiology and pathogenesis of hereditary cardiomyopathy. Circ J Suppl A:A38–48Google Scholar
  22. 22.
    Duboscq-Bidot L, Charron P, Ruppert V et al (2009) Mutations in the ANKRD1 gene encoding CARP are responsible for human dilated cardiomyopathy. Eur Heart J 30(17):2128–2136PubMedCrossRefGoogle Scholar
  23. 23.
    Maekawa Y, Ouzounian M, Opavsky MA, Liu PP (2007) Connecting the missing link between dilated cardiomyopathy and viral myocarditis: virus, cytoskeleton, and innate immunity. Circulation 115(1):5–8PubMedCrossRefGoogle Scholar
  24. 24.
    Linde A, Mosier D, Blecha F, Melgarejo T (2007) Innate immunity and inflammation—new frontiers in comparative cardiovascular pathology. Cardiovasc Res 73(1):26–36PubMedCrossRefGoogle Scholar
  25. 25.
    Mann DL (2011) The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls. Circ Res 108(9):1133–1145PubMedCrossRefGoogle Scholar
  26. 26.
    Maisch B, Richter A, Koelsch S et al (2006) Management of patients with suspected (peri-) myocarditis and inflammatory dilated cardiomyopathy. Herz 31:881–890PubMedCrossRefGoogle Scholar
  27. 27.
    Cooper LT, Baughman KL, Feldman AM et al (2007) The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation 116:2216–2233PubMedCrossRefGoogle Scholar
  28. 28.
    Pankuweit S, Moll R, Baandrup U et al (2003) Prevalence of the parvovirus B19 genome in endomyocardial biopsy specimens. Hum Pathol 34:497–450PubMedCrossRefGoogle Scholar
  29. 29.
    Kühl U, Pauschinger M, Noutsias M et al (2005) High prevalence of viral genomes and multiple viral infections in the myocardium of adults with “idiopathic” left ventricular dysfunction. Circulation 11:887–893CrossRefGoogle Scholar
  30. 30.
    Küthe F, Lindner J, Matwschke K et al (2009) Prevalence of parvovirus B19 and human bocavirus DNA in the heart of patients with no evidence of dilated cardiomyopathy or myocarditis. Clin Infect Dis 49:1660–1666CrossRefGoogle Scholar
  31. 31.
    Stewart GC, Lopez-Molina J, Gottumukkala RV et al (2011) Myocardial parvovirus B19 persistence: lack of association with clinicopathologic phenotype in adults with heart failure. Circ Heart Fail 4(1):71–78PubMedCrossRefGoogle Scholar
  32. 32.
    Maisch B, Ristic AD, Hufnagel G et al (2002) Dilated cardiomyopathies as a cause of congestive heart failure. Herz 27:113–134PubMedCrossRefGoogle Scholar
  33. 33.
    Maisch B, Ristic AD, Portig I, Pankuweit S (2003) Human viral cardiomyopathy. Front Biosci 8:39–67CrossRefGoogle Scholar
  34. 34.
    Maisch B, Outzen H, Roth D, Hiby A et al (1991) Prognostic determinants in conventionally treated myocarditis and perimyocarditis—focus on antimyolemmal antibodies. Eur Heart J 12(Suppl B):81–87PubMedGoogle Scholar
  35. 35.
    Kindermann I, Kindermann M, Kandolf R et al (2008) Predictors of outcome in patients with suspected myocarditis. Circulation 118:639–648PubMedCrossRefGoogle Scholar
  36. 36.
    Schulz-Menger J, Maisch B, Abdel-Aty H et al (2007) Integrated biomarkers in cardiomyopathies: cardiovascular magnetic resonance imaging combined with molecular and immunologic markers. A stepwise approach for diagnosis and treatment. Herz 32:458–472PubMedCrossRefGoogle Scholar
  37. 37.
    Maisch B, Bülowius U, Schmier K et al (1985) Immunological cellular regulator and effector mechanisms in myocarditis. Herz 10:8–14PubMedGoogle Scholar
  38. 38.
    Maisch B, Berg PA, Kochsiek K (1980) Autoantibodies and serum inhibition factors (SIF) in patients with myocarditis. Klin Wochenschr 58(5):219–225PubMedCrossRefGoogle Scholar
  39. 39.
    Maisch B, Trostel-Soeder R, Berg PA, Kochsiek K (1981) Assessment of antibody mediated cytolysis of vital adult cardiocytes isolated by centrifugation in a continuous gradient of Percoll™ in patients with acute myocarditis. J Immunol Methods 44:159–169PubMedCrossRefGoogle Scholar
  40. 40.
    Maisch B, Trostel-Soeder R, Stechemesser E et al (1982) Diagnostic relevance of humoral and cell-mediated immune reactions in patients with acute viral myocarditis. Clin Exp Immunol 48:533–545PubMedGoogle Scholar
  41. 41.
    Maisch B, Herzum M, Schönian U (1993) Immunomodulating factors and immunosuppressive drugs in the therapy of myocarditis. Scand J Infect Dis Suppl 88:149–162PubMedGoogle Scholar
  42. 42.
    Maisch B, Ristic AD, Hufnagel G, Pankuweit S (2002) Pathophysiology of viral myocarditis: the role of humoral immune response. Cardiovasc Pathol 11(2):112–122PubMedCrossRefGoogle Scholar
  43. 43.
    Maisch B (1985) Surface antigens of adult heart cells and their use in diagnosis. Basic Res Cardiol 80(Suppl 1):47–52PubMedCrossRefGoogle Scholar
  44. 44.
    Maisch B (1987) The sarcolemma as antigen in the secondary immunopathogenesis of myopericarditis. Eur Heart J 8(Suppl J):155–165Google Scholar
  45. 45.
    Maisch B, Drude L, Hengstenberg C et al (1991) Are antisarcolemmal (ASAs) and antimyolemmal antibodies (AMLAs) “natural” antibodies? Basic Res Cardiol 86(Suppl 3):101–114PubMedGoogle Scholar
  46. 46.
    Maisch B, Drude L, Hengstenberg C et al (1992) Cytolytic anticardiac membrane antibodies in the pathogenesis of myopericarditis. Postgrad Med J 68(Suppl 1):11–16Google Scholar
  47. 47.
    Maisch B, Bauer E, Cirsi M, Kochsiek K (1993) Cytolytic cross-reactive antibodies directed against the cardiac membrane and viral proteins in coxsackievirus B3 and B4 myocarditis. Characterization and pathogenetic relevance. Circulation 87(Suppl 5):IV49–65PubMedGoogle Scholar
  48. 48.
    Maisch B (1989) Autoreactivity to the cardiac myocyte, connective tissue and the extracellular matrix in heart disease and postcardiac injury. Springer Semin Immunopathol 11:369–395PubMedGoogle Scholar
  49. 49.
    Maisch B, Deeg P, Liebau G, Kochsiek K (1983) Diagnostic relevance of humoral and cytotoxic immune reactions in primary and secondary dilated cardiomyopathy. Am J Cardiol 52:1072–1078PubMedCrossRefGoogle Scholar
  50. 50.
    Maisch B, Wedeking U, Kochsiek K (1987) Quantitative assessment of antilaminin antibodies in myocarditis and perimyocarditis. Eur Heart J 8(Suppl J):223–235Google Scholar
  51. 51.
    Obermayer U, Scheidler J, Maisch B (1987) Antibodies against micro- and intermediate filaments in carditis and dilated cardiomyopaty—are they a diagnostic marker? Eur Heart J. 8(Suppl J):181–186Google Scholar
  52. 52.
    Wittner B, Maisch B, Kochsiek K (1983) Quantification of antimyosin antibodies in experimental myocarditis by a new solidphase fluorometric assay. J Immunol Methods 64:239–247PubMedCrossRefGoogle Scholar
  53. 53.
    Klein R, Maisch B, Kochsiek K, Berg PA (1984) Demonstration of organ specific antibodies against heart mitochondria (anti M7) in sera from patients with some forms of heart diseases. J Clin Exp Immunol 58:283–292Google Scholar
  54. 54.
    Schultheiss HP, Bolte HD (1988) Immunological analysis of autoantibodies against the adenine nucleotide translocator in dilated cardiomyopathy. J Mol Cell Cardiol 17:603–617CrossRefGoogle Scholar
  55. 55.
    Pohlner K, Portig I, Pankuweit S et al (1997) Identification of mitochondrial antigens recognized by the antibodies in sera of patients with dilated cardiomyopathy by two-dimensional gel electrophoresis and protein sequencing. Am J Cardiol 80:1040–1045PubMedCrossRefGoogle Scholar
  56. 56.
    Pankuweit S, Pohlner K, Lottspeich F et al (1997) Identification of mitochondrial antigens recognized by antibodies in sera of patients with dilated cardiomyopathy by two—dimensional gel electrophoresis and protein sequencing. Am J Cardiol 80:1040–1045PubMedCrossRefGoogle Scholar
  57. 57.
    Pankuweit S, Portig I, Lottspeich F et al (1997) Autoantibodies in sera of patients with myocarditis: characterization of the corresponding proteins by isoelectric focusing and N-terminal sequence analysis. J Mol Cell Cardiol 29:77–84PubMedCrossRefGoogle Scholar
  58. 58.
    Portig I, Pankuweit S, Maisch B (1997) Antibodies against stressproteins in the sera of patient with dilated cardiomyopathy. J Mol Cell Cardiol 29(8):2245–2251PubMedCrossRefGoogle Scholar
  59. 59.
    Wallukat G, Wollenberg A, Morwinski R, Pitschner HF (1995) Anti-beta1-adrenoceptor autoantibodies with chronotropic activity from the serum of patients with dilated cardiomyopathy: mapping of epitopes in the first and second extracellular loops. J Mol Cell Cardiol 27:397–406PubMedCrossRefGoogle Scholar
  60. 60.
    Magnusson Y, Wallukat G, Waagstein F et al (1994) Autoimmunity in idiopathic dilated cardiomyopathy. Characterization of antibodies against the beta1-adrenoceptor with positive chronotropic effect. Circulation 89:2760–2767PubMedCrossRefGoogle Scholar
  61. 61.
    Christ T, Wettwer E, Dobrev D et al (2001) Autoantibodies against the beta1-adrenoceptor from patients with dilated cadiomyopathy prolong action ptoential duration and enhance contractility in isolated cardiomyocytes. J Mol Cell Cardiol 33:1515–1525PubMedCrossRefGoogle Scholar
  62. 62.
    Jahns R, Boivin V, Siegmund C et al (1999) Autoantibodies activating human beta 1-adrenergic receptors are associated with reduced cardiac function in chronic heart failure. Circulation 99:649–654PubMedCrossRefGoogle Scholar
  63. 63.
    Jahns R, Bolvin V, Hein L et al (2004) Direct evidence for a beta1—adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest 113:1419–1429PubMedGoogle Scholar
  64. 64.
    Fu LXM, Magnusson Y, Bergh CH et al (1993) Localization of a functional autoimmune epitope on the second extracellular loop of the human muscarinic actylcholin receptor 2 in patients with idiopathic dilated cardiomyopathy. J Clin Invest 91:1964–1968PubMedCrossRefGoogle Scholar
  65. 65.
    Maisch B, Lotze U, Schneider J, Kochsiek K (1986) Antibodies to human sinus node in sick-sinus syndrome. Pace 9(Part II):1101–1109PubMedCrossRefGoogle Scholar
  66. 66.
    Lotze U, Maisch B (1989) Humoral immune response to cardiac conducting tissue. Springer Semin Immunopathol 11:409–422PubMedCrossRefGoogle Scholar
  67. 67.
    Caforio AL, Goldman JH, Haven AJ et al (1996) Evidence for autoimmunity to myosin and other heart-specific autoantigens in patients with dilated cardiomyopathy and their relatives. Int J Cardiol 54:157–163PubMedCrossRefGoogle Scholar
  68. 68.
    Caforio AL, Tona F, Bottaro S et al (2008) Clinical implications of anti-heart autoantibodies in myocarditis and dilated cardiomyopathy. Autoimmunity 41(1):35–45 (Review)PubMedCrossRefGoogle Scholar
  69. 69.
    Maisch B (1996) Alkohol und Herz. Herz 21:207–212PubMedGoogle Scholar
  70. 70.
    Menz V, Grimm W, Hoffmann J, Maisch B (1996) Alcohol and rhythm disturbance: the holiday heart syndrome. Herz 21:227–231PubMedGoogle Scholar
  71. 71.
    Rupp H, Brilla CG, Maisch B (1996) Hypertonie und Alkohol: zentrale und periphere Mechnismen. Herz 21:258–264PubMedGoogle Scholar
  72. 72.
    Wilke A, Kaiser A, Ferency I, Maisch B (1996) Alkohol und Myokarditis. Herz 21:248–257PubMedGoogle Scholar
  73. 73.
    Aneja A, Tang WH, Bansilal S et al (2008) Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med 121(9):748–757PubMedCrossRefGoogle Scholar
  74. 74.
    Bertoni AG, Tsai A, Kasper EK, Brancati FL (2003) Diabetes and idiopathic cardiomyopathy: a nationwide case-control study. Diabetes Care 26:2791–2795PubMedCrossRefGoogle Scholar
  75. 75.
    Maisch B (2006) Obesity, diabetes mellitus and metabolic syndrome: the implications for heart and the vascular system. Herz 31(3):185–188PubMedCrossRefGoogle Scholar
  76. 76.
    Maisch B, Alter P, Pankuweit S (2011) Diabetic cardiomyopathy—fact or fiction? Herz 36:102–115PubMedCrossRefGoogle Scholar
  77. 77.
    Matucci-Cerinic M, Seferovic PM (2006) Heart involvement in autoimmune rheumatic diseases: the ‘‘phantom of the opera’’. Rheumatology (Oxford) 45(Suppl 4):iv1–iv3Google Scholar
  78. 78.
    Maisch B (1992) The heart in rheumatic disease. In: Baenkler HW (edds) Rheumatic diseases and sport. Rheumatology. Karger, Basel 16:81–117Google Scholar
  79. 79.
    Maisch B, Pankuweit S, Karatolios K, Ristić AD (2006) Invasive techniques—from diagnosis to treatment. Rheumatology (Oxford) 45(Suppl 4):iv32–iv38Google Scholar
  80. 80.
    Maksimovic’ R, Seferovic’ PM, Ristic’AD et al (2006) Cardiac imaging in rheumatic diseases. Rheumatology (Oxford) 45(Suppl 4):iv26–31Google Scholar
  81. 81.
    Jacobson DL, Gange SJ, Rose NR et al (1997) Epidemiology and estimated population burden of selected autoimmune disease in the United States. Clin Immunol Immunopathol 84:223–243PubMedCrossRefGoogle Scholar
  82. 82.
    Whittacre CC (2001) Sex differences in autoimmune disease. Nat Immunol 2:777–780CrossRefGoogle Scholar
  83. 83.
    Portig I, Sandmoller A, Pankuweit S, Maisch B (2005) Women and autoimmune diseases with cardiovascular manifestations. Herz 30(6):522–526PubMedCrossRefGoogle Scholar
  84. 84.
    Hufnagel G, Maisch B, Pfeiffer U (1987) Immunhistologic investigations in suspected cardiac sarcoidosis. Eur Heart J 8(Suppl J):59–62Google Scholar
  85. 85.
    Maisch B, Selmayer N, Brugger E et al (1987) Cardiac sarcoidosis—clinical and immunoserologic studies. Eur Heart J 8(Suppl J):63–71Google Scholar
  86. 86.
    Schoppet M, Pankuweit S, Moll R et al (2002) Images in cardiovascular medicine. Phenotype of infiltrating T lymphocytes in cardiac sarcoidosis. Circulation 105(12):e67–68PubMedCrossRefGoogle Scholar
  87. 87.
    Schoppet M, Pankuweit S, Maisch B (2003) Cardiac sarcoidosis: cytokine patterns in the course of the disease. Arch Pathol Lab Med 127(9):1207–1210PubMedGoogle Scholar
  88. 88.
    Cunningham MW (2000) Pathogenesis of group a streptococcal infections. Clin Microbiol Rev 13:470–511PubMedCrossRefGoogle Scholar
  89. 89.
    Tontsch D, Pankuweit S, Maisch B (2000) Autoantibodies in the sera of patients with rheumatic heart disease: characterization of myocardial antigens by two-dimensional immunoblotting and N-terminal sequence analysis. Clin Exp Immunol 121(2):270–274PubMedCrossRefGoogle Scholar
  90. 90.
    Ellis NM, Li Y, Hildebrand W et al (2005) T cell mimicry and epitope specificity of cross-reactive T cell clones from rheumatic heart disease. J Immunol 175:5448–5456PubMedGoogle Scholar
  91. 91.
    Faé KC, Diefenbach da Silva D, Bilate AM et al (2008) PDIA3, HSPA5 and vimentin, proteins identified by 2-DE in the valvular tissue, are the target antigens of peripheral and heart infiltrating T cells from chronic rheumatic heart disease patients. J Autoimmun 31:136–141PubMedCrossRefGoogle Scholar
  92. 92.
    Special Writing Group of the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council of Cardiovascular Disease in the Young of the American Heart Association (1992) Guidelines for the diagnosis of rheumatic fever. Jones Criteria, 1992 update. JAMA 268(15):2069–2073CrossRefGoogle Scholar
  93. 93.
    Maisch B (2011) Cardiovascular disease in cancer patients—only the tip of the iceberg? Herz 4:287–289CrossRefGoogle Scholar
  94. 94.
    Curigliano G, Mayer EL, Burstein HJ et al (2010) Cardiac toxicity from systemic cancer therapy: a comprehensive review. Prog Cardiovasc Dis 53:94–104PubMedCrossRefGoogle Scholar
  95. 95.
    Shi A, Moon M, Dawood S et al (2011) Mechanisms and management of doxorubicin cardiotoxicity. Herz 4:296–305CrossRefGoogle Scholar
  96. 96.
    Wittig A, Engenhart-Cabillic R (2011) Cardiac side effects of conventional and particle radiotherapy in cancer patients. Herz 4:311–324CrossRefGoogle Scholar
  97. 97.
    Schultheiss HP, Kühl U, Cooper LT (2011) The management of myocarditis. Eur Heart J 32:2616–2625PubMedCrossRefGoogle Scholar
  98. 98.
    Huber SA, Lodge PA (1986) Coxsackievirus B-3-myocarditis. Identification of different pathogenic mechanisms in DBA/2 and Balb/c mice. Am J Pathol 122:284–291PubMedGoogle Scholar
  99. 99.
    Herzum M, Ruppert V, Kuytz B et al (1994) Coxsackievirus B3 infection leads to cell death of cardiac myocytes. J Mol Cell Cardiol 26(7):907–913PubMedCrossRefGoogle Scholar
  100. 100.
    Bergelson JM, Cunningham JA, Droguett G et al (1997) Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275:1320–1323PubMedCrossRefGoogle Scholar
  101. 101.
    Bergelson JM, Chan M, Solomon KR et al (1994) Decay accelerating factor (CD55), a glycosylphosphatidylinositol-anchored complement regulatory protein, is a receptor for several echoviruses. Proc Natl Acad Sci U S A 91:6245–6249PubMedCrossRefGoogle Scholar
  102. 102.
    Badorff C, Lee GH, Lamphear BJ et al (1999) Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med 5:320–326PubMedCrossRefGoogle Scholar
  103. 103.
    Fuse K, Chan G, Liu Y et al (2005) Myeloid differentiation factor-88 plays a crucial role in the pathogenesis of Coxsackievirus B3-induced myocarditis and influences type I interferon production. Circulation 112:2276–2285PubMedCrossRefGoogle Scholar
  104. 104.
    Fairwheather D, Rose NR (2007) Coxsackievirus-induced myocarditis in mice: a model of autoimmune disease for studying immunotoxicity. Methods 41:118–122CrossRefGoogle Scholar
  105. 105.
    Frisancho-Kiss S, Davis SE, Nyland JF et al (2007) Cutting edge: cross-regulation by TLR4 and T cell Ig mucin-3 determines sex differences in inflammatory heart disease. J Immunol 178:6710–6714PubMedGoogle Scholar
  106. 106.
    Godeny EK, Gauntt CJ (1987) Murine natural killer cells limit coxsackievirus B3 replication. J Immunol 139:913–918PubMedGoogle Scholar
  107. 107.
    Seko Y, Tsuchimochi H, Nakamura T et al (1990) Expression of major histocompatibility complex class I antigen in murine ventricular myocytes infected with Coxsackievirus B3. Cir Res 67:360–367CrossRefGoogle Scholar
  108. 108.
    Seko Y, Matsuda H, Kato K et al (1993) Expression of intercellular adhesion molecule-1 in murine hearts with acute myocarditis caused by coxsackievirus B3. J Clin Invest 91:1327–1336PubMedCrossRefGoogle Scholar
  109. 109.
    Seko Y, Yagita H, Okumura K, Yazaki Y (1994) T-cell receptor V beta expression in infiltrating cells in murine hearts withs acute myocarditis caused by coxsackievirus B3. Circulation 89:2170–2175PubMedCrossRefGoogle Scholar
  110. 110.
    Huber SA, Feldman AM, Sartini D (2006) Coxsackievirus B3 induces T regulatory cells, which inhibit cardiomyopathy in tumor necrosis factor-alpha transgenic mice. Circ Res 99:1109–1116PubMedCrossRefGoogle Scholar
  111. 111.
    Li K, Xu W, Guo Q et al (2009) Differential macrophage polarization in male and female BALB/c mice infected with coxsackievirus B3 defines susceptibility to viral myocardits. Circ Res 105:353–364PubMedCrossRefGoogle Scholar
  112. 112.
    Huber SA, Job LP (1983) Cellular immune mechanisms in Coxsackievirus group B, type 3 included myocarditis in BALB/C mice. Adv Exp Biol 161:491–508CrossRefGoogle Scholar
  113. 113.
    Seko Y, Takahashi N, Ishiyama S et al (1998) Expression of costimulatory molecules B7–1, B7–2, and CD40 in the heart of patients with acute myocarditis and dilated cardiomyopathy. Circulation 97:637–639PubMedCrossRefGoogle Scholar
  114. 114.
    Takata S, Nakamura H, Umemoto S et al (2004) Identification of autoantibodies with the corresponding antigen for repetitive coxsackievirus infection-induce cardiomyopathy. Circ J 68:677–682PubMedCrossRefGoogle Scholar
  115. 115.
    Latif N, Baker CS, Dunn MJ et al (1993) Frequency and specifity of antiheart antibodies in patients with dilated cardiomyopathy detected using SDS-PAGE and western blotting. J Am Coll Cardiol 22:1378–1384PubMedCrossRefGoogle Scholar
  116. 116.
    Latif N, Zhang H, Archard LC et al (1999) Characterization of anti-heart antibodies in mice after infection with coxsackie B3 virus. Clin Immunol 91:90–98PubMedCrossRefGoogle Scholar
  117. 117.
    Young NS, Brown KE (2004) Mechanisms of disease. Parvovirus B19. N Engl J Med 350:586–597PubMedCrossRefGoogle Scholar
  118. 118.
    Saint-Martin I, Choulot JJ, Bonnau E, Morinet F (1990) Myocarditis caused by parvovirus. J Pediatr 116:1007–1008PubMedGoogle Scholar
  119. 119.
    Nigro G, Bastianon V, Colloridl V et al (2000) Human parvovirus B19 infection in infancy associated with acute and chronic lymphocytic myocarditis and high cytokine levels: report of 3 cases and review. Clin Infect Dis 13:65–69CrossRefGoogle Scholar
  120. 120.
    Schowengerdt KO, Ni J, Denfield SW et al (1997) Association of parvovirus B19 genome in children with myocarditis and cardiac allograft rejection: diagnosis using the polymerase chain reaction. Circulation 3549–3554Google Scholar
  121. 121.
    Lamparter S, Schoppet M, Pankuweit S, Maisch B (2003) Acute parvovirus B19 infection associated with myocarditis in an immunocompetent adult. Hum Pathol 34(7):725–728PubMedCrossRefGoogle Scholar
  122. 122.
    Bock CT, Klingel K, Kandolf R (2010) Human parvovirus B19-associated myocarditis. N Engl J Med 362:213–214CrossRefGoogle Scholar
  123. 123.
    Salahuddin SZ (1986) Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders. Science 234(4776):596–601PubMedCrossRefGoogle Scholar
  124. 124.
    Krueger GRF, Ablashi DV (2003) Human herpesvirus-6: a short review of its biological behavior. Intervirology 46:257–269PubMedCrossRefGoogle Scholar
  125. 125.
    Buja LM (2006) HHV-6 in cardiovascular pathology. Chapter 18. In: Krueger GRF, Ablashi DV (eds) Human herpesvirus-6, 2nd edn. Elsevier Sci Publ, Amsterdam, pp 233–241Google Scholar
  126. 126.
    Fukae S, Ashizawa N, Morikawa S, Yano K (2000) A fatal fulminant myocarditis with human herpesvirus-6 infection. Intern Med 39(8):632–636PubMedCrossRefGoogle Scholar
  127. 127.
    De Ona M, Melon S, Rodriguez JL et al (2002) Association between human herpervirus type 6 and type 7, and cytomegalovirus disease in heart transplant recipients. Transplant Proc 34:75–76CrossRefGoogle Scholar
  128. 128.
    Komaroff AL (2006) Is human herpesvirus-6 a trigger for chronic fatigue syndrome? J Clin Virol 37(Suppl 1):39–46CrossRefGoogle Scholar
  129. 129.
    Schönian U, Crombach M, Maisch B (1993) Assessment of cytomegalovirus DNA and protein expression in patients with myocarditis. Clin Immuol Immunopathol 68:229–233CrossRefGoogle Scholar
  130. 130.
    Schönian U, Crombach M, Maisch B (1991) Does CMV infection play a role in myocarditis? New aspects from in-situ hybridization. Eur Heart J 12(Suppl D):65–68PubMedGoogle Scholar
  131. 131.
    Matsumori A, Yutani C, Ikeda Y et al (2000) Sasayama: hepatitis C virus from the hearts of patients with myocarditis and cardiomyopathy. Lab Invest 80(7):1137–1142PubMedCrossRefGoogle Scholar
  132. 132.
    Barbaro G, Di Lorenzo G, Soldini M et al (1999) Intensity of myocardial expression of inducible nitric oxide synthase influences the clinical course of human immunodeficiency virus-associated cardiomyopathy. Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS (GISCA). Circulation 100(9):933–939PubMedCrossRefGoogle Scholar
  133. 133.
    Liebermann EB, Hutchin GM, Herskowitz A et al (1991) Clinico-pathologic description of myocarditis. J Am Coll Cardiol 18:1617–1626CrossRefGoogle Scholar
  134. 134.
    Friedrich MG, Sechtem U, Schulz-Menger J et al. for the International Consensus Group on Cardiovascular Magnetic Resonance in Myocarditis (2009) Cardiovascular magnetic resonance in myocarditis: a JACC white paper. J Am Coll Cardiol 53:1475–1487PubMedCrossRefGoogle Scholar
  135. 135.
    Maisch B, Alter P, Romminger M et al (2011) MRI or EMB for the diagnosis of myocarditis and viral heart disease. EHJ suppl (Abstract supplement of the ESC Congress)Google Scholar
  136. 136.
    Mahrholdt H, Goedecke C, Wagner A et al (2004) Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation 109:1250–1258PubMedCrossRefGoogle Scholar
  137. 137.
    Maisch B, Seferovic PM, Ristic AD et al (2004) Task force on the diagnosis and management of pericardial diseases of the European Society of Cardiology. Guidelines on the diagnosis and management of pericardial diseases executive summary; the Task force on the diagnosis and management of pericardial diseases of the European Society of Cardiology. Eur Heart J 25(7):587–610PubMedCrossRefGoogle Scholar
  138. 138.
    Maisch B, Ristic AD, Seferovic PM, Tsang TSM (2011) Interventional pericardiology. Pericardiocentesis, pericardioscopy, pericardial biopsy, balloon pericardiotomy and intrapericardial therapy. Springer Medizin, HeidelbergGoogle Scholar
  139. 139.
    Horowitz MDS, Schultz CS, Stinson EB et al (1974) Sensitivity and specificity of echocardiographic diagnosis of pericardial effusion. Circulation 50:239–245PubMedCrossRefGoogle Scholar
  140. 140.
    Baughman KL (2006) Diagnosis of myocarditis: death of dallas criteria. Circulation 113:593–595PubMedCrossRefGoogle Scholar
  141. 141.
    Maisch B, Hufnagel G, Schönian U, Hengstenberg C (1995) The European Study of Epidemiology and Treatment of Cardiac Inflammatory Disease (ESETCID). Eur Heart J 16(Suppl O):173–175PubMedGoogle Scholar
  142. 142.
    Burch GE (1972) Prolonged bed rest in the management of patients with cardiomyopathy. Cardiovasc Clin 4:376–387Google Scholar
  143. 143.
    Burch GE, McDonald CD (1971) Prolonged bed rest in the treatment of ischemic cardiomyopathy. Chest 60:424–430PubMedCrossRefGoogle Scholar
  144. 144.
    Hunt SA, American College of Cardiology, American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation, Management of Heart Failure) (2005) ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). JACC 46(6):e1–e82PubMedGoogle Scholar
  145. 145.
    Hunt SA, Abraham WT, Chin MH et al (2009) 2009 Fucussed update incorporated into the ACC/AHA 2005 Guidelines for the diagnosis and management of heart failure in adults. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 53:e31–e90CrossRefGoogle Scholar
  146. 146.
    Dickstein K, Cohen-Solal A, Filippatos G et al (2008) ESC Guidelines for th eidagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensiv Cardiac Care Medicine (ESICM). Eur Heart J 29:2388–2442PubMedCrossRefGoogle Scholar
  147. 147.
    Packer M (1992) The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 20:248–254PubMedCrossRefGoogle Scholar
  148. 148.
    CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril-Survival Study (CONSENSUS). N Engl J Med 316:1429–1435CrossRefGoogle Scholar
  149. 149.
    Pfeffer MA, Braunwald E, Moye LA et al (1992) Effect of captopril on mortality and morbidity in patients with lef ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 327:669–677PubMedCrossRefGoogle Scholar
  150. 150.
    SOLVD Investigators (1992) Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327:685–691CrossRefGoogle Scholar
  151. 151.
    Packer M, Poole-Wilson PA, Armstrong PW et al (1999) Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 100:2312–2318PubMedCrossRefGoogle Scholar
  152. 152.
    Yusuf S, Sleight P, Pogue J et al (2000) Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study (HOPE) Investigators. N Engl J Med 342:145–153PubMedCrossRefGoogle Scholar
  153. 153.
    Pfeffer MA, Swedberg K, Granger CB et al (2003) Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall program. Lancet 362:759–766PubMedCrossRefGoogle Scholar
  154. 154.
    Yusuf S, Pfeffer MA, Swedberg K et al (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362:777–781PubMedCrossRefGoogle Scholar
  155. 155.
    Pitt B, Poole-Wilson PA, Segal R et al (2000) Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial. The Losartan Heart Failure Survaival Study ELITE II. Lancet 355:1582–1587PubMedCrossRefGoogle Scholar
  156. 156.
    Rezkalla SH, Raikar S, Kloner RA (1996) Treatment of viral myocarditis with focus on captopril. Am J Cardiol 77:634–637PubMedCrossRefGoogle Scholar
  157. 157.
    Saegusa S, Fei Y, Takahashi T et al (2007) Oral administration of candesartan improves the survival of mice with viral myocarditis through modification of cardiac adiponectin expression. Cardiovasc Drugs Ther 21:155–160PubMedCrossRefGoogle Scholar
  158. 158.
    Weber KT, Brilla CG (1991) Pathogical hypertrophy and cardiac insterstitium. Fibrosis and rennin-angiotensin-aldosterone system. Circulation 83:1849–1865PubMedCrossRefGoogle Scholar
  159. 159.
    Maisch B, Rupp H (2006) Myocardial fibrosis: a cardiopathophysiologic Janus head. Herz 31(3):260–268PubMedCrossRefGoogle Scholar
  160. 160.
    Waagstein F, Hjalmarson A, Varnauskas E, Walentin L (1975) Effect of beta-adrenergic receptor blockade in congestive cardiomyoapthy. Br Heart J 37:1022–1036PubMedCrossRefGoogle Scholar
  161. 161.
    Swedberg K, Hjalmarson A, Waagstein F, Wallentin I (1980) Adverse effects of beta-blockade withdrawal in patients with congestive cardiomyopathy. Br Heart J 44:134–142PubMedCrossRefGoogle Scholar
  162. 162.
    MERIT-HF Study Group (1999) Effect of metoprolo CR/XL in chronic heart failure. Metprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001–2007CrossRefGoogle Scholar
  163. 163.
    CIBIS-II Investigators and Committee (1999) The cardiac insufficiency bisoprolol Study II (CIBIS-II): a radomised trial. Lancet 353:9–13CrossRefGoogle Scholar
  164. 164.
    Packer M, Coats AJ, Fowler MB et al (2001) Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651–1658PubMedCrossRefGoogle Scholar
  165. 165.
    Pitt B, Zannad F, Remme WJ et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341:709–717PubMedCrossRefGoogle Scholar
  166. 166.
    Pitt B, Remme W, Zannad F et al (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309–1321PubMedCrossRefGoogle Scholar
  167. 167.
    Swedberg K, Komajda M, Böhm M et al (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376:875–885PubMedCrossRefGoogle Scholar
  168. 168.
    Digitalis Investigation Group (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336:525–533CrossRefGoogle Scholar
  169. 169.
    Costanzo-Nordin MR, Reap EA, Robinson JA, Scanlon PJ (1985) A nonsteroid anti-inflammatory drug exacerbates Coxsackie B3 murine myocarditis. J Am Coll Cardiol 6:1078–1082PubMedCrossRefGoogle Scholar
  170. 170.
    Cardiac Arrhythmia Suppression Trial (1989) Increase mortality due to encainide or flecainide in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321:406–412CrossRefGoogle Scholar
  171. 171.
    Amiodarone Trials Meta-Analysis Investigators (1997) Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomized trials. Lancet 350:1417–1424CrossRefGoogle Scholar
  172. 172.
    Bardy GH, Lee KL, Mark DB et al (2005) Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352:225–237PubMedCrossRefGoogle Scholar
  173. 173.
    Hohenloser SH, Kuck KH, Lilienthal J for the PIAF Investigators (2000) Rhythm or rate control in atrial fibrillation: Pharmacological Intervention in Atrial Fibrillation (PIAF). A randomized trial. Lancet 356:1789–1794CrossRefGoogle Scholar
  174. 174.
    Carlsson J, Miketic S, Windeler J et al (2003) Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation. The Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 41:1690–1696PubMedCrossRefGoogle Scholar
  175. 175.
    Van Gelder IC, Hagens VE, Bosker HA et al (2002) Rate control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347:1834–1840CrossRefGoogle Scholar
  176. 176.
    Wyse DG, Waldo AL, DiMarco JP et al for the Atrial Follow-Up Investigation of Rhythm Management (AFFIRM) Investigators (2002) A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347:1825–1833PubMedCrossRefGoogle Scholar
  177. 177.
    Grimm W, Christ M, Bach J et al (2003) Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: results of the Marburg Cardiomyopathy Study. Circulation 108(23):2883–2891PubMedCrossRefGoogle Scholar
  178. 178.
    Grimm W, Alter P, Maisch B (2004) Arrhythmia risk stratification with regard to prophylactic implantable defibrillator therapy in patients with dilated cardiomyopathy. Results of MACAS, DEFINITE, and SCD-HeFT. Herz 29(3):348–352PubMedCrossRefGoogle Scholar
  179. 179.
    Kadish A, Dyer A, Daubert JP et al (2005) Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyoapthy. N Engl J Med 350:2151–2158CrossRefGoogle Scholar
  180. 180.
    Higgins SL, Hummel JD, Niazi IK et al (2003) Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol 42:1454–1459PubMedCrossRefGoogle Scholar
  181. 181.
    Bristow MR, Saxon LA, Boehmer J et al (2004) Cardiac resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350:2140–2150 (COMPANION)PubMedCrossRefGoogle Scholar
  182. 182.
    Linde C, Leclercq C, Rex S et al (2002) Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation In Cardiomyopathy (MUSTIC) study. J Am Coll Cardiol 40:111–118PubMedCrossRefGoogle Scholar
  183. 183.
    St John Sutton MG, Plappert T, Abraham WT et al (2003) Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation 107:1985–1990CrossRefGoogle Scholar
  184. 184.
    Strauer BE, Brehm M, Zeus T et al (2001) Intrakoronare, humane autologe Stammzelltransplantation zur Myokard-Regeneration nach Herzinfarkt [Myocardial regeneration after intracoronary transplantation of human autologous stem cells following acute myocardial infarction]. Dtsch Med Wschr 126:932–938PubMedCrossRefGoogle Scholar
  185. 185.
    Seth S, Narang R, Bhargava B et al for the AIIMS Cardiovascular Stem Cell Study Group. Percutaneous intracoronary cellular cardiomyoblasty for non-ischemic cardiomyopathy (2006) Clinical and histopathological results. The first-in-man ABCD (Autologous Bone marrow Cells in Dilated cardiomyopathy) trial. J Am Coll Cardiol 48:2350–2351PubMedCrossRefGoogle Scholar
  186. 186.
    Schannwell CM, Köstering M, Zeus T et al (2008) Humane autologe intrakoronare Stammzelltransplantation zur Myokadrregeneration bei dilatativer Kardiomyopathie (NYHA Stadium II bis III) [Autologous bone marrow cells in dilated cardiomyoapthy trial, Düsseldorfer ABCD Study)] J Kardiol 15:23–30Google Scholar
  187. 187.
    Maisch B, Hufnagel G, Kölsch S et al (2004) Treatment of inflammatory dilated cardiomyopathy and myocarditis with immunosuppression and i.v. immunoglobulins. Herz 29:624–636PubMedCrossRefGoogle Scholar
  188. 188.
    Maisch B, Richter A, Koelsch S et al (2006) Management of patients with suspected (peri-) myocarditis and inflammatory dilated cardiomyopathy. Herz 31(9):881–890PubMedCrossRefGoogle Scholar
  189. 189.
    Saltykow S (1905) Über diffuse Myokarditis. Virchows Archiv für Pathologische Anatomie. 182:1–39Google Scholar
  190. 190.
    Ren H, Poston RS, Hruban RH et al (1993) Long survival with giant cell myocarditis. Mod Pathol 6:402–407PubMedGoogle Scholar
  191. 191.
    Frustaci A, Chimenti C, Peironi M et al (2000) Giant cell myocarditis responding to immunosuppressive therapy. Chest 117:905–907PubMedCrossRefGoogle Scholar
  192. 192.
    Cooper LT, Berry GJ, Shabetai R (1997) Idiopathic giant cell myocarditis—natural history and treatment. N Engl J Med 336:1860–1866PubMedCrossRefGoogle Scholar
  193. 193.
    Cooper L, Okura Y (2001) Idiopathic giant cell myocarditis. Curr Treat Options Cardiovasc Med 3:463–467PubMedCrossRefGoogle Scholar
  194. 194.
    Okada R, Wakafuji S (1985) Myocarditis in autopsy. Heart Vessels Suppl 1:23–29PubMedCrossRefGoogle Scholar
  195. 195.
    Kodama M, Matsumoto Y, Fujiwara M et al (1990) A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction. Clin Immunol Immunopathol 57:250–262PubMedCrossRefGoogle Scholar
  196. 196.
    Kodama M, Hanawa H, Saeki M et al (1994) Rat dilated cardiomyopathy after autoimmune giant cell myocarditis. Circ Res 75:278–284PubMedCrossRefGoogle Scholar
  197. 197.
    Okura Y, Yamamoto T, Goto S et al (1997) Characterization of cytokine and iNOS mRNA expression in situ during the course of experimental autoimmune myocarditis in rats. J Mol Cell Cardiol 29:491–502PubMedCrossRefGoogle Scholar
  198. 198.
    Izumi T, Takehana H, Kohno K et al (2003) Myosin autoreactive T cells and autoimmune myocarditis. Lessons from the disease caused by cardiac myosin peptide CM2. In: Matsumori A (ed) Cardiomyopathies and heart failure. Luwer Academic Publ, pp 59–65Google Scholar
  199. 199.
    Cooper LT, Berry GHJ, Shabetai R (1997) Giant cell myocarditis: distinctions from lymphocytic myocarditis and cardiac sarcoidosis. J Heart Failure 4:227–230Google Scholar
  200. 200.
    Costanzo-Nordin M, Silver M, O’Connell J et al (1987) Giant cell myocarditis: dramatic hemodynamic and histologic improvement with immunosuppressive therapy. Eur Heart J (Suppl J):271–274Google Scholar
  201. 201.
    Desjardins V, Pelletier G, Leung TK et al (1992) Successful treatment of severe heart failure caused by idiopathic giant cell myocarditis. Can J Cardiol 8:788–792PubMedGoogle Scholar
  202. 202.
    Nash C, Panaccione R, Sutherland L et al (2001) Giant cell myocarditis in a patient with Crohn’s disease, treated with Etanercept—a tumor necrosis factor-alpha antagonist. Canadian J Gastroenterol 15:607–611Google Scholar
  203. 203.
    Brilakis E, Olson LJ, Daly RC et al (1999) Role of ventricular assist device support as a bridge to transplantation in giant cell myocarditis. J Heart Lung Transplant 18:31CrossRefGoogle Scholar
  204. 204.
    Grant SC (1993) Recurrent giant cell myocarditis after transplantation. J Heart Lung Transplant 12:155–156PubMedGoogle Scholar
  205. 205.
    Scott R, Ratliff N, Starling R et al (2001) Recurrence of giant cell myocarditis in cardiac allograft. J Heart Lung Transplant 20:375–380PubMedCrossRefGoogle Scholar
  206. 206.
    Cooper LT, Berry GJ, Tazelaar H et al (1998) A comparison of post-transplantation survival in giant cell myocarditis and cardiomyopathy patients. J Am Coll Cardiol 29:251ACrossRefGoogle Scholar
  207. 207.
    Okura Y, Dec GW, Hare JM et al (2003) A clinical and histopathologic comparison of cardiac sarcoidosis and idiopathic giant cell myocarditis. J Am Coll Cardiol 41:322–328PubMedCrossRefGoogle Scholar
  208. 208.
    Hufnagel G, Maisch B, Pfeiffer U (1987) Immunhistologic investigations in suspected cardiac sarcoidosis. Eur Heart J 8(Suppl J):59–62Google Scholar
  209. 209.
    Sekiguchi M, Numao Y, Imai M et al (1980) Clinical and histopathological profile of sarcoidosis of the heart and acute idiopathic myocarditis. Concepts through a study employing endomyocardial biopsy. I. Sarcoidosis. Jpn Circ J 44:249–263PubMedCrossRefGoogle Scholar
  210. 210.
    Schoppet M, Pankuweit S, Moll R et al (2002) Images in cardiovascular medicine. Phenotype of infiltrating T lymphocytes in cardiac sarcoidosis. Circulation 105(12):e67–8PubMedCrossRefGoogle Scholar
  211. 211.
    Schoppet M, Pankuweit S, Maisch B (2003) Cardiac sarcoidosis. Cytokine patterns in the course of the disease. Arch Pathol Lab Med 127:1207–1210PubMedGoogle Scholar
  212. 212.
    Valentonye R, Hampe J, Huse K et al (2005) Sarcoidosis is associated with a truncating splice mutant in BTNL2. Nat Genetics 37:357–364CrossRefGoogle Scholar
  213. 213.
    Meyer T, Lauschke J, Ruppert V et al (2008) Isolated cardiac sarcoidosis associated with the expression of a splice variant coding for a truncated BTNL2 protein. Cardiology 109(2):117–121PubMedCrossRefGoogle Scholar
  214. 214.
    Ardehali H, Howard DL, Hariri A et al (2005) A positive endomyocardial biopsy result for sarcoid is associated with poor prognosis in patients with initially unexplained cardiomyopathy. Am Heart J 150:459–463PubMedCrossRefGoogle Scholar
  215. 215.
    Bargout R, Kelly RF (2004) Sarcoid heart disease. Clinical course and treatment. Int J Cardiol 97:173–182PubMedCrossRefGoogle Scholar
  216. 216.
    Löffler W (1936) Endocarditis parietalis fibroplastica mit Bluteosinophilie. Ein eigenartiges Krankheitsbild. Schweizerische medizinische Wochenschrift Basel 66:817–820Google Scholar
  217. 217.
    Oakley CM, Olsen GJ (1977) Eosinophilia and heart disease. Br Heart J 39(3):233–237PubMedCrossRefGoogle Scholar
  218. 218.
    Olsen EG, Spry CJ (1985) Relation between eosinophilia and endomyocardial disease. Prog Cardiovasc Dis 27(4):241–254PubMedCrossRefGoogle Scholar
  219. 219.
    Parrillo JE (1990) Heart disease and the eosinophil. N Engl J Med 323(22):1560–1561PubMedCrossRefGoogle Scholar
  220. 220.
    Parrillo JE, Borer JS, Henry WL et al (1979) The cardiovascular manifestations of the hypereosinophilic syndrome. Am J Med 67:572–582PubMedCrossRefGoogle Scholar
  221. 221.
    Fauci AS, Harley JB, Roberts WC et al (1982) NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med 97(1):78–92PubMedGoogle Scholar
  222. 222.
    Gotlib J (2011) World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management. Am J Hematol 86(8):677–688PubMedCrossRefGoogle Scholar
  223. 223.
    Maisch B, Baandrup U, Moll R, Pankuweit S (2009) Eosinophilic carditis is rare but not to be overlooked. EHJ Suppl XX, 2009 AbstractGoogle Scholar
  224. 224.
    Gleich GJ, Frigas E, Loegering DA et al (1979) Cytotoxic properties of the eosinophil major basic protein. J Immunol 123(6):2925–2927PubMedGoogle Scholar
  225. 225.
    Tai PC, Ackerman SJ, Spry CJ et al (1987) Deposits of eosinophil granule proteins in cardiac tissues of patients with eosinophilic endomyocardial disease. Lancet 1(8534):643–647PubMedCrossRefGoogle Scholar
  226. 226.
    Spry CJ, Tai PC, Davies J (1983) The cardiotoxicity of eosinophils. Postgrad Med J 59(689):147–153PubMedCrossRefGoogle Scholar
  227. 227.
    Slungaard A, Vercellotti GM, Tran T et al (1993) Eosinophil cationic granule proteins impair thrombomodulin function. A potential mechanism for thromboembolism in hypereosinophilic heart disease. J Clin Invest 91(4):1721–1730PubMedCrossRefGoogle Scholar
  228. 228.
    Ohnishi T, Kita H, Weiler D et al (1993) IL-5 is the predominant eosinophil-active cytokine in the antigen- induced pulmonary late-phase reaction. Am Rev Respir Dis 147(4):901–907PubMedGoogle Scholar
  229. 229.
    Ommen S, Seward J, Tajik A (2000) Clinical and echocardiographic features of hypereosinophilic syndromes. Am J Cardiol 86:110–113PubMedCrossRefGoogle Scholar
  230. 230.
    Shah R, Ananthasubramaniam K (2006) Evaluation of cardiac involvement in hypereosinophilic syndrome: complementary roles of transthoracic, transesophageal, and contrast echocardiography. Echocardiography 23:689–691PubMedCrossRefGoogle Scholar
  231. 231.
    Del Bene MR, Cappelli F, Rega L et al (2012) Characterization of Loeffler eosinophilic myocarditis by means of real time three-dimensional contrast-enhanced echocardiography. Echocardiography 29(3):E62–66CrossRefGoogle Scholar
  232. 232.
    Syed IS, Martinez MW, Feng DL et al (2008) Cardiac magnetic resonance imaging of eosinophilic endomyocardial disease. Int J Cardiol 126:e50–e52PubMedCrossRefGoogle Scholar
  233. 233.
    Kleinfeldt T, Ince H, Nienaber CA (2011) Hypereosinophilic syndrome: a rare case of Loeffler’s endocarditis documented in cardiac MRI. Int J Cardiol 149(1):e30–e32PubMedCrossRefGoogle Scholar
  234. 234.
    Paydar A, Ordovas KG, Reddy GP (2008) Magnetic resonance imaging for endomyocardial fibrosis. Pediatr Cardiol 29(5):1004–1005PubMedCrossRefGoogle Scholar
  235. 235.
    Deb K, Djavidani B, Luchner A et al (2008) Time course of eosinophilic myocarditis visualized by CMR. J Cardiovasc Magn Reson 10(1):21–25CrossRefGoogle Scholar
  236. 236.
    Uetsuka Y, Kasahara S, Tanaka N et al (1990) Hemodynamic and scintigraphic improvement after steroid therapy in a case with acute eosinophilic heart disease. Heart Vessels Suppl 5:8–12PubMedGoogle Scholar
  237. 237.
    Butterfield JH, Gleich GJ (1994) Interferon-alpha treatment of six patients with the idiopathic hypereosinophilic syndrome. Ann Intern Med 121(9):648–653PubMedGoogle Scholar
  238. 238.
    Metzgeroth G, Walz C, Reiter A et al (2008) Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome—a phase-II study. Br J Haematol 143(5):707–715PubMedCrossRefGoogle Scholar
  239. 239.
    Abonia JP, Putnam PE (2011) Mepolizumab in eosinophilic disorders. Expert Rev Clin Immunol 7(4):411–417PubMedCrossRefGoogle Scholar
  240. 240.
    Garrett JK, Jameson SC, Thomson B et al (2004) Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol 113(1):115–119PubMedCrossRefGoogle Scholar
  241. 241.
    Rothenberg M, Klion A, Gleich G et al (2008) Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 358(12):1215–1228PubMedCrossRefGoogle Scholar
  242. 242.
    Edwards WD, Holmes DR, Reeder GS (1982) Diagnosis of active lymphocytic myocarditis by endomyocardial biopsy. Quantitative criteria for light microscopy. Mayo Clin Proc 57:419–425PubMedGoogle Scholar
  243. 243.
    Fenoglio JJ, Ursell PC, Kellogg CF et al (1983) Diagnosis and classification of myocarditis by endomyocardial biopsy. N Engl J Med 308:12–18PubMedCrossRefGoogle Scholar
  244. 244.
    Dec quoted in Batra AS, Lewis AB (2001) Acute myocarditis. Curr Opin Pediatr 13:234–239CrossRefGoogle Scholar
  245. 245.
    Hosenpud JD, McAnulty JH, Niles NR (1985) Lack of objective improvement in ventricular systolic function in patients with myocarditis treated with azathioprine and prednisone. J Am Coll Cardiol 6:217–222CrossRefGoogle Scholar
  246. 246.
    Anderson quoted in Maisch B, Herzum M, Schoenian U (1993) Immunomodulating factors and immunosuppressive drugs in the therapy of myocarditis. Scand J Infect Dis Suppl 88:149–162Google Scholar
  247. 247.
    Marboe CC, Fenoglio JJ Jr (1988) Pathology and natural history of human myocarditis. Pathol Immunopathol Res 7:226–239PubMedCrossRefGoogle Scholar
  248. 248.
    Latham RD, Mulrow JP, Virmani R et al (1989) Recently diagnosed idiopathic dilated cardiomyopathy: incidence of myocarditis and efficacy of prednisone therapy. Am Heart J 117:876–882PubMedCrossRefGoogle Scholar
  249. 249.
    Maisch B, Schoenian U, Hengstenberg C et al (1994) Immunosuppressive therapy in autoreactive myocarditis: Results from a controlled trial. Postgrad Med J 70(Suppl 1):29–34Google Scholar
  250. 250.
    Kühl U, Strauer BE, Schultheiss H-P (1994) Methylprednisolone in chronic myocarditis. Postgrad Med J 70(Suppl 1):35–42Google Scholar
  251. 251.
    Camargo PR, Snitcowsky R, da Luz PL et al (1995) Favorable effects of immunosuppressive therapy in children with dilated cardiomyopathy and active myocarditis. Pediatr Cardiol 16:61–68PubMedCrossRefGoogle Scholar
  252. 252.
    Liu Dezue (2002) Observation of integrated Chinese traditional and Western medicine on acute viral myocarditis. Xian Dai Zhong Xi Yi Jie He Za Zhi 11:481–482Google Scholar
  253. 253.
    Liu Dezue, Yang Lei, Jiang Haixia (2003) Clinical search of Sheng Mai injection combined with corticosteroids for acute viral myocarditis in children. J Sichuan Tradit Chin Med 21:59–60Google Scholar
  254. 254.
    Sun Dabao (1999) Corticosteroid treatment effects in 36 cases diagnose with viral myocarditis with ventricle premature beats. J Zhenjiang Medical College 9:211Google Scholar
  255. 255.
    Wu Yo-zang, Chen Bing-wang (1999) Observation on curative effects of astragalus injection combined with glucocorticoids on acutely severe viral myocarditis. Zhongguo Zhong Xe Yi Jie He Ji Jui Za Zhi 6:350–352Google Scholar
  256. 256.
    Kong Qing-fu, Song Shu-zhi, Xie Xue-ying et al (2001) Clinical study on therapeutic effects of treatment according to syndrome differentiation of traditional Chinese medicine combined with captopril on severe viral myocarditis complicated heart failure. Zhongguo Zhong Xi Yi Jie He Za Zhi 21:513–515PubMedGoogle Scholar
  257. 257.
    Frustaci A, Calabrese F, Chimenti C et al (2003) Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile for responders versus nonresponders. Circulation 107:857–863PubMedCrossRefGoogle Scholar
  258. 258.
    Parillo JE, Cunnion RE, Epstein SE et al (1989) A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med 321:1061–1068CrossRefGoogle Scholar
  259. 259.
    Mason JW, O’Connel JB, Hershkowitz A et al (1995) A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 33:269–275CrossRefGoogle Scholar
  260. 260.
    Brown CA, O’Connel JB (1996) Implications of the myocarditis treatment trial for clinical practice. Curr Opin Cardiol 11:332–336PubMedCrossRefGoogle Scholar
  261. 261.
    Maisch B, Camerini F, Schultheiss H-P (1955) Immunosuppressive therapy for myocarditis (letter). N Engl J Med 333:1713Google Scholar
  262. 262.
    Wojnicz R, Nowalany-Koziolaska E, Wojciechowska C et al (2001) Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy. Two-year follow-up results. Circulation 104:39–45PubMedCrossRefGoogle Scholar
  263. 263.
    Frustaci A, Russo MA, Chimenti C (2009) Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J 30:1995–2002PubMedCrossRefGoogle Scholar
  264. 264.
    Maisch B, Kölsch S, Hufnagel G, Funck RC, Ruppert V, Pankuweit S for the ESETCID Investigators, Orlando 2011, AHA Congress, AbstractGoogle Scholar
  265. 265.
    Anthony RM, Nimmerjahn F, Ashline DJ et al (2008) Recapitulation of IVIG anti-inflammatory activity with a recombinant Ig Fc. Science 320:373–376PubMedCrossRefGoogle Scholar
  266. 266.
    Ballow M (1997) Mechanisms of actin of intrvenous immune serum globulin in autoimmune and inflammatory diseases. J Allergy Clin Immunol 100:151–157PubMedCrossRefGoogle Scholar
  267. 267.
    Dalakas MC (2004) Intravenous immunoglobulin in autoimmune neuromuscular disease. JAMA 291:2367–2375PubMedCrossRefGoogle Scholar
  268. 268.
    Nimmerjahn F, Ravetsch JV (2008) Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 26:513–533PubMedCrossRefGoogle Scholar
  269. 269.
    Kzatchkine MD, Kaveri SV (2001) Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345:747–755CrossRefGoogle Scholar
  270. 270.
    Rosen FS (1993) Putative mechanisms oft he effect of intravenous gamma-globulin. Clin Immunol Immunopathol 67:41–43CrossRefGoogle Scholar
  271. 271.
    Mobini N, Sarela A, Ahmed AR (1995) Intravenous immunoglobulins in the therapy of autoimmune and systemic inflammatory disorders. Ann Allergy Asthma Immunol 74:119–128PubMedGoogle Scholar
  272. 272.
    Gold R, Stangel M, Dalakas MC (2007) Drug insight: the use of intravenous immunoglobulin in neurology-therapeutic considerations and practical issues. Nat Clin Pract Neurol 3:36–44PubMedCrossRefGoogle Scholar
  273. 273.
    Selbing A, Josefsson A, Dahle LO, Lindgren R (1995) Parvovirus B19 infection during pregnancy treated with high-dose intravenous gammaglobulin. Lancet 345:660–661PubMedCrossRefGoogle Scholar
  274. 274.
    Gullestad L, Aass H, Fjeld JG et al (2001) Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 103:220–225PubMedCrossRefGoogle Scholar
  275. 275.
    Aukrust P, Yndestad A, Ueland T et al (2006) The role of intravenous immunoglobulin in the treatment of chronic heart failure. Int J Cardiol 112(1):40–45PubMedCrossRefGoogle Scholar
  276. 276.
    Udi N, Yehuda S (2008) Intravenous immunoglobulin—indications and mechanisms in cardiovascular diseases. Autoimmun Rev 7(6):445–452PubMedCrossRefGoogle Scholar
  277. 277.
    Walpen AJ, Laumonier T, Aebi C et al (2004) IgM enriched intravenous immunoglobulin inhibits classical pathway complement activation, but not bacterial killing by human serum. Xenotransplantation 11(2):141–148PubMedCrossRefGoogle Scholar
  278. 278.
    Kishimoto C, Fujita M, Kinoshita M et al (1999) Immunglobulin therapy for myocarditis an acute dilated cardiomyopathy. Circulation 100(18):1405Google Scholar
  279. 279.
    Kishimoto C, Shioji K, Kinoshita M et al (2003) Treatment of acute inflammatory cardiomyopathy with intravenous immunoglobulin ameliorates left ventricular function associated with suppression of inflammatory cytokines and decreased oxidative stress. Int J Cardiol 91:173–178PubMedCrossRefGoogle Scholar
  280. 280.
    Robinson J, Hartling L, Crumley E et al (2005) A systematic review of intravenous gamma globulin for the therapy of acute myocarditis. BMC Cardiovasc Disord 5:12–18PubMedCrossRefGoogle Scholar
  281. 281.
    Bozkurt B, Villaneuva FS, Holubkov R et al (1999) Intravenous immune globulin in the therapy of peripartum cardiomyopathy. J Am Coll Cardiol 34:177–180PubMedCrossRefGoogle Scholar
  282. 282.
    Takeda Y, Yasuda S, Miyazaki S et al (1998) High-dose immunoglobulin G therapy for fulminant myocarditis. Jpn Circ J 62:871–872PubMedCrossRefGoogle Scholar
  283. 283.
    Goland S, Czer LSC, Siegel RJ et al (2008) Intravenous immunoglobulin treatment for acute fulminant inflammatory cardiomyopathy: series of sixpatients and review of literature. Can J Cardiol 24(7):571–574PubMedCrossRefGoogle Scholar
  284. 284.
    Drucker NA, Colan SD, Lewis AB et al (1994) Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation 89:252–257PubMedCrossRefGoogle Scholar
  285. 285.
    McNamara DM, Rosenblum WD, Janosko KM et al (1997) Intravenous immune gobulin in the therapy of myocarditis and acute cardiomyopathy. Circulation 95:2476–2478PubMedCrossRefGoogle Scholar
  286. 286.
    McNamara DM, Holubkov R, Starling RC et al for the Intervention in Myocarditis and Acute Cardiomyopathy (IMAC) Investigators (2001) Controlled trial of intravenous immune globuline in recent-onset dilated cardiomyopathy. Circulation 103:2254–2259PubMedCrossRefGoogle Scholar
  287. 287.
    Shioji K, Matsuura Y, Iwase T et al (2002) Successful immunoglobulin treatment for fulminant myocarditis and serial analysis of serum thiredoxin—a case report. Circulation J 66:977–980CrossRefGoogle Scholar
  288. 288.
    Tedeschi A, Liraghi L, Giannini S et al (2002) High-dose intravenous immunoglobulin in the treatment of acute myocarditis. A case report and review of the literature. J Intern Med 251:169–173PubMedCrossRefGoogle Scholar
  289. 289.
    Tsai YG, Ou TY, Wang CC et al (2001) Intravenous gamma-globulin therapy in myocarditis complicated with complete heart block: report of one case. Chung-Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Ts Chih 42:311–313Google Scholar
  290. 290.
    Shioji K, Kishimoto C, Sasyama S (2000) Immunoglobulin therapy for acute myocarditis. Respiration Circulation 48(11):1133–1139Google Scholar
  291. 291.
    Takada H, Kishimoto C, Hiraoka Y (1995) Therapy with immunoglobulin suppresses myocarditis in a murine coxsackievirus B3 model—antiviral and anti-inflammatory effects. Circulation 92(6):1604–1611PubMedCrossRefGoogle Scholar
  292. 292.
    Nigro G, Bastianon V, Coloridi V et al (2000) Human parvovirus B19 infection in infancy associated with acute and chronic lymphocytic myocarditis and high cytokine levels: report of 3 cases and review. Clin Infect Dis 31:65–69PubMedCrossRefGoogle Scholar
  293. 293.
    Dennert R, Velthuis S, Schalla S et al (2010) Intravenous immunoglobulin therapy for patients with idiopathic cardiomyoapthy and endomyocardial biopsy-proven high PVB19 viral load. Antivir Ther 15:193–201PubMedCrossRefGoogle Scholar
  294. 294.
    Wang C, Luf FL, Wu M et al (2004) Fatal coxsackievirus A16 infection. Pediatr. Infect Dis J 23:275–276CrossRefGoogle Scholar
  295. 295.
    Klugman D, Berger JT, Sable CA et al (2009) Pediatric patients hospitalized with myocarditis: a multi-institutional analysis. Pediatr Cardiol 31:222–228CrossRefGoogle Scholar
  296. 296.
    Maisch B, Pankuweit S, Funck R, Koelsch S (2004) Effective CMV hyperimmunoglobulin treatment in CMV myocarditis—a controled treatment trial. Eur Heart J (Abstract Suppl:114,P674.abstract)Google Scholar
  297. 297.
    Alter P, Grimm W, Maisch B (2001) Varicella myocarditis in an adult. Heart 85:E2PubMedCrossRefGoogle Scholar
  298. 298.
    Wallukat G, Müller J, Hetzer R (2002) Specific removal of beta1-adrenergic autoantibodies from patients with idiopathic dilated cardiomyopathy. N Engl J Med 347:1806PubMedCrossRefGoogle Scholar
  299. 299.
    Wallukat G, Reinke P, Dorffel WV et al (1996) Removal of autoantibodies in dilated cardiomyopathy by immunoadsorption. Int J Cardiol 54:191–195PubMedCrossRefGoogle Scholar
  300. 300.
    Felix SB, Staudt A, Dorffel WV et al (2000) Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study. J Am Coll Cardiol 35:1590–1598PubMedCrossRefGoogle Scholar
  301. 301.
    Müller J, Wallukat G, Dandel M et al (2000) Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation 101:385–391PubMedCrossRefGoogle Scholar
  302. 302.
    Staudt Y, Mobini R, Fu M et al (2003) β1-Adrenoceptor antibodies induce apoptosis in adult isolated cardiomyocytes. Eur J Pharmacol 423:115–119CrossRefGoogle Scholar
  303. 303.
    Felix SB, Staudt A, Landsberger M et al (2002) Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption. J Am Coll Cardiol 39:646–652PubMedCrossRefGoogle Scholar
  304. 304.
    Staudt A, Böhm M, Knebel F et al (2002) Potential role of autoantibodies belonging to the immunoglobulin G-3 subclass in cardiac dysfunction among patients suffering from dilated cardiomyopathy. Circulation 106:2448–2453PubMedCrossRefGoogle Scholar
  305. 305.
    Staudt A, Schaper F, Stangl V et al (2001) Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption therapy and subsequent immunoglobulin substitution. Circulation 103:2681–2686PubMedCrossRefGoogle Scholar
  306. 306.
    Trimpert C, Herda LR, Eckerle LG et al (2010) Immunoadsorption in dilated cardiomyopathy: long-term reduction of cardiodepressant antibodies. Eur J Clin Invest 20:685–691CrossRefGoogle Scholar
  307. 307.
    Kallwellis-Opara A, Staudt A, Trimpert C et al (2007) Immunoadsorption and subsequent immunoglobulin substitution decreases myocardial gene expression of desmin in dilated cardiomyopathy. J Mol Med 85:1429–1435PubMedCrossRefGoogle Scholar
  308. 308.
    Fohlman J et al (1990) Vaccination of Balb/c mice against enteroviral mediated myocarditis. Vaccine 8:381–384PubMedCrossRefGoogle Scholar
  309. 309.
    Fohlmann J, Pauksen K, Morein B et al (1993) High yield production of an inactivated Coxsackie B3 adjuvant vaccine with protective effect against experimental myocarditis. Scand J Infect Dis Suppl 88:103–108Google Scholar
  310. 310.
    McKinlay MA (1993) Discovery and development of antipicorna viral agents. Scand J Infect Dis (Suppl 88):109–115Google Scholar
  311. 311.
    Ilbäck N-G, Wesslen L, Pauksen K et al (1993) Effects of the antiviral WIN 54954 and the immune modulator LS 2616 on cachectin/TNF and g-interferon responses during viral heart disease. Scand J Infect Dis (Suppl 88):117–123Google Scholar
  312. 312.
    Kühl U, Pauschinger M, Schwimmbeck PL (2003) Interferon-beta treatment eliminates cardiotropic viruses and improves left ventriclar function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 107:2793–2798PubMedCrossRefGoogle Scholar
  313. 313.
    Schmidt-Lucke C, Spillmann F, Bock T et al (2010) Interferon-beta modulates endothelial damage in patients with cardiac persistance of parvovirus B19. J Infect Dis 201:936–945PubMedCrossRefGoogle Scholar
  314. 314.
    Schultheiss HP, Piper C, Sowade K et al (2009) The effect of subcutaneous treatment with interferon-beta1b over 24 weeks on safety, virus elimination and clinical outcome in patients with chronic viral cardiomyopathy. Eur Heart J 30:1995–2002CrossRefGoogle Scholar
  315. 315.
    Maisch B, Ristic AD, Pankuweit S (2002) Intrapericardial treatment of autoreactive pericardial effusion with triamcinolone; the way to avoid side effects of systemic corticosteroid therapy. Eur Heart J 23(19):1503–1508PubMedCrossRefGoogle Scholar

Copyright information

© Urban & Vogel 2012

Authors and Affiliations

  1. 1.Department of Internal Medicine and CardiologyUniversity Hospital Gießen & MarburgMarburgGermany

Personalised recommendations